Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Strategic AAV Vector Design for Preclinical Programs in Switzerland

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Strategic AAV Vector Design for Preclinical Programs in Switzerland

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in Translational Vector Science.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Executive Summary

For Swiss biotechs advancing next-generation therapeutics, the design of the viral vector directly influences preclinical success and regulatory alignment. A vector strategy conceived with the entire translational pathway in mind : from initial promoter and capsid selection to the analytical methods required for GxP-compliant toxicology studies : impacts the integrity of nonclinical data packages for Swissmedic, EMA, and FDA submissions. This approach mitigates risks associated with immunogenicity, biodistribution, and long-term expression, accelerating typical 18-24 month IND timelines.

Frequently Asked Questions

How does vector design impact preclinical toxicology outcomes for AAV therapies?

Vector design directly influences the safety profile evaluated in IND-enabling toxicology studies. Choices regarding the capsid (e.g., AAV8, AAV9, or engineered variants), promoter, and transgene cassette dictate tissue tropism, expression levels, and potential immunogenicity. A well-designed vector minimizes non-target tissue biodistribution and ensures that the expression profile in nonhuman primate (NHP) models is representative of the intended human clinical outcome, generating a cleaner, more interpretable dataset for regulators.

What is the typical timeline for moving from a research-grade vector to an IND submission with a Swiss or EU focus?

While timelines vary, our integrated approach targets an 18-24 month path to IND or IMPD submission. This is achieved by overlapping strategic vector design with the planning of preclinical translational services. By developing the vector with a scalable, GxP-compliant process in mind from the start, we avoid the significant delays that occur when a research-grade process must be completely re-engineered for clinical manufacturing.

For a Swiss biotech, how do you ensure vector manufacturing aligns with both FDA and EMA/Swissmedic expectations?

We design and execute programs that adhere to harmonized international guidelines (ICH). Our process development and analytical strategies generate a single, robust data package suitable for multi-jurisdictional submissions. This includes phase-appropriate qualification of assays and manufacturing processes that meet the rigorous standards of all major regulatory bodies, ensuring a unified path forward for global clinical trials.

Aligning Vector Biology with Preclinical Endpoints

The transition from a research concept to a clinical candidate requires constructing the AAV vector with translatability as a core objective, alongside efficacy. Early decisions in vector element selection have cascading effects on the entire preclinical program. For instance, codon optimization of a transgene, as demonstrated in preclinical work on AAV8 vectors for OTC deficiency, can directly enhance the functional output from each vector genome that persists in target tissues (PMID: 22133298). This optimization strengthens the therapeutic hypothesis before commitment to expensive and lengthy GxP toxicology studies.

A forward-thinking vector strategy anticipates the questions that global regulators will ask. This involves:

  • Capsid Selection: Choosing a serotype with a well-characterized tropism and immunogenicity profile in relevant species, particularly in nonhuman primate models.

  • Promoter & Regulatory Elements: Engineering a cassette that drives durable, tissue-specific expression to maximize therapeutic benefit while minimizing risks from expression in non-target tissues.

  • Manufacturing Readiness: Ensuring the vector construct is compatible with scalable suspension-based manufacturing platforms to support future clinical and commercial demand.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

An Integrated Programmatic Approach

A successful preclinical program depends on both a high-quality vector and an integrated ecosystem of resources. This model was proven effective by programs like the Gene Therapy Resource Program (GTRP), which provided investigators with comprehensive vector production, pharmacology, and toxicology support (PMID: 29130351). This same philosophy underpins our operational model, providing a cohesive scientific extension to our partners.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… This transition has made Franklin Biolabs an integral part of our AAV-vector based gene therapy candidate development, and we hope to continue the partnership for years to come.”
– Biotech Partner

This continuity of expertise is central to our ability to de-risk programs. Our scientific leadership and core team carry forward the track record that achieved a 100% successful IND rate since 2019, prior to the formal launch of Franklin Biolabs in 2024. This history, combined with our >100,000 sq ft of dedicated laboratory and vivarium space, provides the scientific and operational infrastructure needed to support complex programs, including our work with partners like our partners.

By integrating vector design directly with our Vector | CMC | Analytics Services, we ensure that the material produced for pivotal preclinical studies is truly representative of the final clinical product, satisfying a key requirement for Swissmedic, EMA, and FDA reviewers.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities